

Ultraviolet related deoxyribonucleic acid damage in skin of patients with atopic dermatitis and atopic status in relation to the use of Myfortic®

Submission date 22/11/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 22/11/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 05/12/2006	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M S de Bruin-Weller

Contact details
University Medical Center Utrecht
Department of Dermatology
HPN G02 124
P.O. Box 85500
Utrecht
Netherlands
3508 GA
+31 (0)30 2509111
m.s.debruin-weller@umcutrecht.nl

Additional identifiers

Protocol serial number
14196

Study information

Scientific Title

Acronym

Effect of Myfortic® on UV-induced DNA-damage and atopic status

Study objectives

Our hypothesis is that in patients with atopic dermatitis which use topical tacrolimus 0.1% the repair of DeoxyriboNucleic Acid (DNA)-damage in the skin is delayed. The repair of DNA-damage in the skin of patients with atopic dermatitis which use a class II corticosteroid is not delayed.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Clinical Trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Atopic dermatitis

Interventions

Ten patients in total with atopic dermatitis are to be included in the study. The inclusion takes place after the physician has indicated that treatment with oral immunosuppressive drugs is necessary. The informed consent intake will be performed by the researcher. At inclusion a screening will be done to evaluate the severity of the eczema and the atopic state (total and specific Immunoglobulin E [IgE], skin-prick test and atopy patch test) of the patient.

Subsequently we will compare UV-irradiated, non-lesional skin prior to treatment (control) to UV-irradiated, non-lesional skin treated with Myfortic® during 12 weeks (intervention). The Minimal Erythema Dose (MED) will be determined prior to actual irradiation. Punch biopsies will be taken immediately after irradiation with two MED and after 24 hours. A reference biopsy will be taken from skin that is not irradiated. The whole process will be repeated after 12 weeks of treatment.

To evaluate the atopic status after 12 weeks of treatment, we will repeat the skin-prick test and atopy patch test. The final clinical evaluation of therapy will be performed after 16 weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Myfortic®

Primary outcome(s)

The difference between the percentage in repair of Cyclobutane Pyrimidine Dimers (CPD's) before and after treatment with Myfortic® is the primary study outcome.

Key secondary outcome(s)

1. The atopic state before and after treatment with Myfortic®.
2. The evaluation of the efficacy of initial high dosing with Myfortic® in order to induce rapid improvement of the disease.

Completion date

01/05/2007

Eligibility**Key inclusion criteria**

1. Age from 18 years
2. Atopic dermatitis according to the criteria of Hanifin and Rajka
3. Insufficient response to topical therapy alone
4. The physician estimates that treatment with oral immunosuppressive agents is indicated

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

1. Patients with any known hypersensitivity to mycophenolic acid or other components of the formulation
2. Oral immunosuppressive treatment in the last six weeks
3. Concomitant Ultraviolet (UV) therapy or UV therapy in the last two months
4. Contact with UV on the lesional skin for the last two months
5. Patients with thrombocytopenia (less than $75,000/\text{mm}^3$), with an absolute neutrophil count less than $1,500/\text{mm}^3$ and/or leukocytopenia (less than $2,500/\text{mm}^3$) and/or haemoglobin less than 6.0 g/dl prior to enrolment

6. Patients who have received an investigational drug within two weeks prior to screening
7. Patients with a history of malignancy within the last five years
8. Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception
9. Patients with an immunologic disorder (like Rheumatoid Arthritis [RA], Systemic Lupus Erythematosus [SLE] or M. Sjögren) or a pre-existent dermatologic disorder that worsens in combination with UV (like LE or photosensitive eczema)
10. Presence of clinically significant infection requiring continued therapy, severe diarrhoea or uncontrolled diabetes mellitus that would interfere with the appropriate conduct of the study

Date of first enrolment

01/10/2006

Date of final enrolment

01/05/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

University Medical Center Utrecht

Utrecht

Netherlands

3508 GA

Sponsor information

Organisation

University Medical Center Utrecht (UMCU) (The Netherlands)

ROR

<https://ror.org/0575yy874>

Funder(s)

Funder type

Industry

Funder Name

Novartis Pharma B.V.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes